Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis

dc.contributor.authorPalomo, I
dc.contributor.authorPereira, J
dc.contributor.authorAlarcón, M
dc.contributor.authorVásquez, M
dc.contributor.authorPinochet, C
dc.contributor.authorVélez, MT
dc.contributor.authorSandoval, J
dc.contributor.authorIcaza, G
dc.contributor.authorPierangeli, S
dc.date.accessioned2025-01-21T01:08:11Z
dc.date.available2025-01-21T01:08:11Z
dc.date.issued2004
dc.description.abstractAntiphospholipid antibodies (aPL) are a heterogeneous family of antibodies associated with thrombotic events and other complications. The objective of this study was to investigate the prevalence of aPL in a group of Chilean patients with thrombosis. Two hundred and twenty-six patients with venous and arterial thrombosis and 95 healthy controls were studied. Anticardiolipin (aCL), anti-beta(2) glycoprotein I (anti-beta(2)GPI), and antiprothrombin (aPT) antibodies were determined. Eighty-eight out of 226 (38.9%) patients with thrombosis had some type of aPL. Fifty-seven patients (25.2%) were positive for aCL, 31 (13.7%) for aPT, and 14 (6.2%) for anti-beta(2)GPI antibodies. Twelve patients (5.3%) were positive for more than one aPL. IgG, IgM and IgA isotypes were observed in aCL, anti-beta(2)GPI, and aPT antibodies. Twenty-six out of 92 (28.3%) patients with venous thrombosis and 31/134 (23.1%) patients with arterial thrombosis were positive for aCL antibodies. With regard to the control group (4/95 = 4.2%), the odd ratios (OR) were 5.2 (1.3-19.8; p0.01) and 5.7 (1.6-22.3; p0.01), respectively. Additionally, we observed statistically significant OR with aPT and anti-beta(2)GPI antibodies; in the first, with venous and arterial thrombosis, and in the second, only with arterial thrombosis. Our results show a significant prevalence of aPL, predominantly aCL and aPT antibodies, in patients with thrombosis. Additionally, aCL and aPT antibodies appear to be a risk factor for venous and arterial thrombosis, and anti-beta(2)GPI antibodies appear to be a risk factor for arterial thrombosis.
dc.fuente.origenWOS
dc.identifier.doi10.1007/s10067-003-0846-7
dc.identifier.issn0770-3198
dc.identifier.urihttps://doi.org/10.1007/s10067-003-0846-7
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/96436
dc.identifier.wosidWOS:000221197100007
dc.issue.numero2
dc.language.isoen
dc.pagina.final133
dc.pagina.inicio129
dc.revistaClinical rheumatology
dc.rightsacceso restringido
dc.subjectantiphospholipid antibodies
dc.subjectanti-beta(2) glycoprotein I antibodies
dc.subjectantiprothrombin antibodies
dc.subjectthrombosis
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePrevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis
dc.typeartículo
dc.volumen23
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files